<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Medical technology</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Mobia debuts on Nasdaq to bring stroke therapy to more patients</title>
      <description>
        <![CDATA[Mobia Medical Inc. began trading on Nasdaq under the ticker MOBI on May 8. The company priced its IPO at the midpoint of its proposed $14 to $16 range, selling 10 million shares at $15 each and raising approximately $150 million. The stock closed at $11.75 its first day of trading, down 21.7%. Mobia has developed Vivistim Paired VNS, a vagus‑nerve stimulation therapy which improves upper-limb function in chronic ischemic stroke survivors with moderate to severe impairments.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730982</guid>
      <pubDate>Fri, 08 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730982-mobia-debuts-on-nasdaq-to-bring-stroke-therapy-to-more-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Mobia-Medical-Vivistim-5-8.webp?t=1778261656" type="image/jpeg" medium="image" fileSize="79665">
        <media:title type="plain">Mobia Medical Vivistim system</media:title>
        <media:description type="plain">Vivistim Paired VNS system. Credit: Mobia Medical Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Roche to acquire Pathai for up to $1.05B</title>
      <description>
        <![CDATA[Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to strengthen its position in digital pathology and enhance its biopharma services. The move builds on a partnership established between the two companies in 2021, and expanded in 2024, to include the development of AI-enabled companion diagnostic algorithms.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730966</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730966-roche-to-acquire-pathai-for-up-to-105b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Roche-building.webp?t=1698088417" type="image/jpeg" medium="image" fileSize="310241">
        <media:title type="plain">Roche building</media:title>
        <media:description type="plain">Credit: F. Hoffmann-La Roche Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>US FDA tries out 1-day inspections</title>
      <description>
        <![CDATA[Even before the U.S. FDA announced its one-day inspection pilot May 6, it already had test-flown 46 of the shorter inspections across several of its centers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730852</guid>
      <pubDate>Thu, 07 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730852-us-fda-tries-out-1-day-inspections</link>
    </item>
    <item>
      <title>China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M</title>
      <description>
        <![CDATA[Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730868</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730868-china-med-tech-raises-star-sports-105m-ipo-cofoe-nabs-133m</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/HK-Star-Sports-IPO-5-6.webp?t=1778095416" type="image/jpeg" medium="image" fileSize="144071">
        <media:title type="plain">​Star Sports Medicine HKEX IPO ceremony</media:title>
        <media:description type="plain">Star Sports Medicine's IPO ceremony on May 5.
Credit: HKEX; x.com – @HKEXGroup</media:description>
      </media:content>
    </item>
    <item>
      <title>Multiple appearances on Priority Watch List leading to action?</title>
      <description>
        <![CDATA[It’s a sure bet when the U.S. Trade Representative releases its annual Special 301 Report that Chile, China, India, Indonesia, Russia and Venezuela will be on the Priority Watch List. The 2026 report was no exception.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730867</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730867-multiple-appearances-on-priority-watch-list-leading-to-action</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Magnifying-glass-on-wooden-table.webp?t=1721409551" type="image/jpeg" medium="image" fileSize="152426">
        <media:title type="plain">Magnifying glass on wooden table</media:title>
      </media:content>
    </item>
    <item>
      <title>Resmed boosts sleep health portfolio with Noctrix buy</title>
      <description>
        <![CDATA[Resmed Corp. has agreed to acquire Noctrix Health Inc. for $340 million, boosting its sleep health portfolio. Noctrix has developed Nidra, a wearable neuromodulation device which treats restless legs syndrome (RLS) without disrupting sleep. With RLS impacting approximately 7% of adults globally, including about 17 million people in the U.S., the technology offers a non-drug option that could potentially treat a significant proportion of this patient population.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730863</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730863-resmed-boosts-sleep-health-portfolio-with-noctrix-buy</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Noctrix-Health-Nidra-system-5-6.webp?t=1778095493" type="image/jpeg" medium="image" fileSize="97350">
        <media:title type="plain">Noctrix Health Nidra system</media:title>
        <media:description type="plain">Nidra, a wearable neuromodulation device for restless legs syndrome. Credit: Noctrix Health Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>MYO technology enables DNA delivery of incretin agonists for durable weight loss</title>
      <description>
        <![CDATA[Researchers from Renbio Inc. and Louisiana State University investigated the delivery of plasmid DNA encoding new glucagon-like peptide-1(GLP-1)-based biologics with MYO (Make Your Own) technology as a new therapeutic strategy. This approach ensures the continuous production of GLP-1-based biologics for an extended period, overcoming the need for weekly dosing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730903</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730903-myo-technology-enables-dna-delivery-of-incretin-agonists-for-durable-weight-loss</link>
    </item>
    <item>
      <title>Sonire starts US study of cancer HIFU after $18M series A </title>
      <description>
        <![CDATA[Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730922</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730922-sonire-starts-us-study-of-cancer-hifu-after-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>MMI’s Symani system treats Alzheimer’s patient in IDE study</title>
      <description>
        <![CDATA[Medical Microinstruments Inc.’s (MMI) Symani surgical system was used to treat a patient with Alzheimer’s disease as part of a study evaluating robotic-enabled microsurgery for the condition. The procedure investigated whether restoring lymphatic drainage pathways in the deep cervical lymph nodes could improve the clearance of harmful neurotoxins believed to contribute to the progression of Alzheimer’s.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730849</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730849-mmis-symani-system-treats-alzheimers-patient-in-ide-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Symani-system-5-5.webp?t=1778015387" type="image/jpeg" medium="image" fileSize="58857">
        <media:title type="plain">Symani system</media:title>
        <media:description type="plain">Symani surgical system. Credit: Medical Microinstruments Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sonire starts US study of cancer HIFU after $18M series A </title>
      <description>
        <![CDATA[Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730769</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730769-sonire-starts-us-study-of-cancer-hifu-after-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Hypervision secures £17M for surgical hyperspectral imaging platform</title>
      <description>
        <![CDATA[Hypervision Surgical Ltd. raised £17 million (US$23 million) in a series A financing round for its platform technology which combines spectral sensing with cloud-enabled AI analytics, to give surgeons real-time insights into tissue physiology during surgery that were previously impossible to see.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730766</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730766-hypervision-secures-17m-for-surgical-hyperspectral-imaging-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Hypervision-Surgical-Hyperspectral-Intelligence-imaging-platform-5-1.webp?t=1777666739" type="image/jpeg" medium="image" fileSize="134946">
        <media:title type="plain">Hypervision Surgical Hyperspectral Intelligence imaging platform</media:title>
        <media:description type="plain">Hypervision’s Hyperspectral Intelligence imaging platform captures information beyond what the human eye, and conventional surgical cameras, can perceive. Credit: Hypervision Surgical Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>EMA launches pilot for breakthrough medical devices in the EU</title>
      <description>
        <![CDATA[The European Medicines Agency (EMA) has launched a pilot program to fast track breakthrough medical devices in the EU and get lifesaving technologies to patients sooner. The program will allow for companies to obtain scientific advice from the expert panels intended to support evidence generation and clinical development of their devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730752</guid>
      <pubDate>Thu, 30 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730752-ema-launches-pilot-for-breakthrough-medical-devices-in-the-eu</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/EMA-icons.webp?t=1619205754" type="image/png" medium="image" fileSize="406915">
        <media:title type="plain">EMA icons</media:title>
      </media:content>
    </item>
    <item>
      <title>Caredx to acquire Naveris for up to $260 million</title>
      <description>
        <![CDATA[Caredx Inc. has agreed to acquire Naveris Inc., a precision oncology diagnostics company, for up to $260 million, as part of its strategy to accelerate growth. The acquisition comes as Caredx, an organ transplant diagnostic firm, reshapes its portfolio, expanding its oncology profile while recently divesting its lab products business.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730687</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730687-caredx-to-acquire-naveris-for-up-to-260-million</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/cancer-AI-diagnostic.webp?t=1745257620" type="image/jpeg" medium="image" fileSize="265878">
        <media:title type="plain">Cancer diagnostic illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730787</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730787-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Cochlear’s 39% stock plunge resets ‘defensive growth’ narrative </title>
      <description>
        <![CDATA[Shares in Aussie hearing implant maker Cochlear Ltd. plummeted nearly 39% April 22 after the company slashed fiscal 2026 earnings guidance and warned that weaker-than-expected demand in developed markets was exposing a more cyclical and discretionary side to its business than investors had assumed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730783</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730783-cochlears-39-stock-plunge-resets-defensive-growth-narrative</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Cochlear-Nucleus-system-4-23.webp?t=1776975450" type="image/jpeg" medium="image" fileSize="214628">
        <media:title type="plain">Cochlear Nucleus system</media:title>
        <media:description type="plain">Nucleus Nexa cochlear implant system. Credit: Cochlear Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Nervonik raises $52.5M to advance PNS system</title>
      <description>
        <![CDATA[Nervonik Inc. raised $52.5 million in a series B financing round for its peripheral nerve stimulation (PNS) system designed to treat patients with chronic pain and other neurological conditions. The funds will be used to support the continued development Nervonik's PNS system, including enhancements to the system’s sensing capabilities, as well as preparations for commercialization.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730673</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730673-nervonik-raises-525m-to-advance-pns-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Gold-dollar-sign-and-blue-circular-arrows.webp?t=1729544931" type="image/jpeg" medium="image" fileSize="126086">
        <media:title type="plain">Gold dollar sign and blue circular arrows</media:title>
      </media:content>
    </item>
    <item>
      <title>Thermo Fisher sells microbiology business for $1B</title>
      <description>
        <![CDATA[Thermo Fisher Scientific Inc. agreed to sell its microbiology business to Astorg, a private equity firm, for approximately $1.075 billion, consisting of cash and a $50 million seller note. The business unit provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730672</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730672-thermo-fisher-sells-microbiology-business-for-1b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Gloved-hand-holding-petri-dish.webp?t=1594325173" type="image/png" medium="image" fileSize="413731">
        <media:title type="plain">Gloved hand holding petri dish in lab</media:title>
      </media:content>
    </item>
    <item>
      <title>Sun Pharma to acquire Merck spinoff Organon for $11.75B</title>
      <description>
        <![CDATA[Sun Pharmaceuticals Industries Ltd. will pay $11.75 billion cash to acquire Organon & Co. The transaction is expected to close in early 2027. The addition of Organon’s women’s health products, legacy drug brands and biosimilars are expected to boost Mumbai, India-based Sun’s global reach. The all-cash buy is also expected to relieve Jersey City, N.J.-based Organon of an $8.6 billion debt pile, accumulated after its debt-laden 2021 spinout from Merck & Co. Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730643</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730643-sun-pharma-to-acquire-merck-spinoff-organon-for-1175b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Three-red-darts-on-target.webp?t=1761844421" type="image/jpeg" medium="image" fileSize="465362">
        <media:title type="plain">Three red darts on target</media:title>
      </media:content>
    </item>
    <item>
      <title>Med-tech companies highlight PFA data as competition intensifies </title>
      <description>
        <![CDATA[New data on pulsed field ablation (PFA) presented at Heart Rhythm 2026 in Chicago over the weekend continue to show the benefits and superiority of the technologies in treating patients with atrial fibrillation. The PFA landscape is fast-evolving and med-tech players are jostling for market share with ever-differentiated platforms looking to attract electrophysiologists.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730642</guid>
      <pubDate>Mon, 27 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730642-med-tech-companies-highlight-pfa-data-as-competition-intensifies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Atrial-fibrillation-illustration.webp?t=1620156165" type="image/png" medium="image" fileSize="398365">
        <media:title type="plain">Atrial fibrillation illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Edwards raises 2026 guidance on strong TAVR performance</title>
      <description>
        <![CDATA[Edwards Lifesciences Corp. raised its full-year 2026 guidance after seeing strong sales in the first quarter, particulalry from its transcatheter aortic valve replacement (TAVR) business. The company now expects sales growth of 9% to 11%, up from prior outlook of 8% to 10%, and adjusted earnings per share of $2.95 to $3.05, compared with earlier guidance of $2.90 to $3.05.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730617</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730617-edwards-raises-2026-guidance-on-strong-tavr-performance</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Sapien_M3-14apr25.webp?t=1777058665" type="image/jpeg" medium="image" fileSize="195288">
        <media:title type="plain">Edwards Lifesciences Sapien M3</media:title>
        <media:description type="plain">Sapien M3 transcatheter mitral valve replacement system. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Pharma industry faces long haul to get return on investment from AI</title>
      <description>
        <![CDATA[Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730716</guid>
      <pubDate>Fri, 24 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730716-pharma-industry-faces-long-haul-to-get-return-on-investment-from-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-drug-development-illustration.webp?t=1776978683" type="image/jpeg" medium="image" fileSize="1049020">
        <media:title type="plain">Glowing neural network inside a transparent capsule surrounded by a large language model</media:title>
      </media:content>
    </item>
    <item>
      <title>Cochlear’s 39% stock plunge resets ‘defensive growth’ narrative </title>
      <description>
        <![CDATA[Shares in Aussie hearing implant maker Cochlear Ltd. plummeted nearly 39% April 22 after the company slashed fiscal 2026 earnings guidance and warned that weaker-than-expected demand in developed markets was exposing a more cyclical and discretionary side to its business than investors had assumed.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730605</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730605-cochlears-39-stock-plunge-resets-defensive-growth-narrative</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Cochlear-Nucleus-system-4-23.webp?t=1776975450" type="image/jpeg" medium="image" fileSize="214628">
        <media:title type="plain">Cochlear Nucleus system</media:title>
        <media:description type="plain">Nucleus Nexa cochlear implant system. Credit: Cochlear Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA, CMS partner to deliver RAPIDly for innovative devices </title>
      <description>
        <![CDATA[The U.S. FDA and CMS are teaming up to give Medicare beneficiaries quicker access to breakthrough medical devices and provide manufacturers with certainty of reimbursement.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730603</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730603-fda-cms-partner-to-deliver-rapidly-for-innovative-devices</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/thumb/CMS-logo-and-website.webp?t=1689968783" type="image/jpeg" medium="image" fileSize="62055">
        <media:title type="plain">CMS logo and website</media:title>
      </media:content>
    </item>
    <item>
      <title>Forsight’s robot-assisted platform to transform cataract surgery</title>
      <description>
        <![CDATA[The first fully robot-assisted cataract surgery recently performed using Forsight Robotics Ltd.’s Jasper platform was not only a “transformative” event and a major “milestone” for the company, but also a “huge step forward for the industry,” Joseph Nathan, co-founder, president and chief medical officer, told <em>BioWorld</em>. With one in two people globally needing cataract surgery and unable to get access to care, robot-assisted platforms hold the potential to increase surgical throughput and broaden access to treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730602</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730602-forsights-robot-assisted-platform-to-transform-cataract-surgery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Joseph-Nathan-co-founder-president-and-chief-medical-officer-Forsight-Robotics-4-23.webp?t=1776975792" type="image/jpeg" medium="image" fileSize="413486">
        <media:title type="plain">Joseph Nathan, co-founder, president, and chief medical officer, Forsight Robotics</media:title>
        <media:description type="plain">Joseph Nathan, co-founder, president and chief medical officer, Forsight Robotics</media:description>
      </media:content>
    </item>
    <item>
      <title>Pharma industry faces long haul to get return on investment from AI</title>
      <description>
        <![CDATA[Artificial intelligence tools are springing up at multiple points along drug discovery and development, but despite the hype, as yet there is minimal return on investment (ROI). “I would say a lot of companies sort of get this big excitement about AI, but then when you look at how much ROI they get, it’s actually very little. And that’s because the workflow and the process, end-to-end, isn’t mapped to really understand where AI can truly make an impact,” said Laura Matz, chief science and technology officer at Merck KGaA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730600</guid>
      <pubDate>Thu, 23 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730600-pharma-industry-faces-long-haul-to-get-return-on-investment-from-ai</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/AI/AI-drug-development-illustration.webp?t=1776978683" type="image/jpeg" medium="image" fileSize="1049020">
        <media:title type="plain">Glowing neural network inside a transparent capsule surrounded by a large language model</media:title>
      </media:content>
    </item>
    <item>
      <title>Boston Sci’s CEO ‘disappointed’ as company cuts 2026 guidance</title>
      <description>
        <![CDATA[Boston Scientific Corp.'s CEO Mike Mahoney said that the year is turning out to be “more challenging” than the company anticipated, prompting a cut to its organic sales growth guidance to 6.5% to 8%, from 10% to 11%. The company also lowered its adjusted earnings-per-share guidance to $3.34 to $3.41, from $3.43 to $3.49 previously. Analysts welcomed the lower guidance seeing it as somewhat of a relief and an opportunity to reset on the back of the company’s share price, which has fallen sharply over the last year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730498</guid>
      <pubDate>Wed, 22 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730498-boston-scis-ceo-disappointed-as-company-cuts-2026-guidance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Boston-Scientific-signage.webp?t=1776891072" type="image/jpeg" medium="image" fileSize="680673">
        <media:title type="plain">Boston Scientific signage </media:title>
        <media:description type="plain">Credit: Boston Scientific Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Med-tech financings steady at $8.8B in Q1, despite volume drop</title>
      <description>
        <![CDATA[Total med-tech financings reached $8.81 billion in the first quarter (Q1) 2026, a 6% decline from $9.33 billion in Q1 2025 but well above the post-downturn lows of recent years. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730573</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730573-med-tech-financings-steady-at-88b-in-q1-despite-volume-drop</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Layered-charts.webp?t=1706913970" type="image/jpeg" medium="image" fileSize="137002">
        <media:title type="plain">Layered  charts </media:title>
      </media:content>
    </item>
    <item>
      <title>Xeltis secures CE mark for Axess, its hemodialysis conduit</title>
      <description>
        <![CDATA[Xeltis BV has secured CE mark approval for Axess, its restorative vascular access conduit for hemodialysis. The company also released 12-month data from its EU pivotal trial on the technology, which showed strong durability outcomes, including 79% secondary patency and a very low patency‑related reintervention rate of 1.3 per patient-year, as well as a substantial reduction in infection burden.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730483</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730483-xeltis-secures-ce-mark-for-axess-its-hemodialysis-conduit</link>
      <media:content url="https://www.bioworld.com/ext/resources/2025/Xeltis-Axess-vascular-access-conduit-8jan25jpg.webp?t=1776800189" type="image/jpeg" medium="image" fileSize="34193">
        <media:title type="plain">Xeltis-Axess-vascular-access-conduit-8jan25jpg.jpg</media:title>
        <media:description type="plain">Axess vascular access conduit. Credit: Xeltis BV</media:description>
      </media:content>
    </item>
  </channel>
</rss>
